Germany takes some pain out of new drug reimbursement
This article was originally published in SRA
Executive Summary
Companies wanting to make it through Germany's early benefit assessment system that was introduced under the AMNOG healthcare reform act will very soon have more freedom to choose which comparator their new drug must go up against in the system's tough benefit assessments. On 5 July, Germany's Bundesrat, the federal council, signed off changes which will come into effect within a few weeks.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.